Published Date: 04 Mar 2024
After a year in a small prospective trial, 91% of cases had local control.
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 5, 2025.
Following stiripentol’s market authorization in Japan in November 2012, a postmarketing surveillance study was conducted in all patients with Dravet syndrome who initiated treatment.
A study reveals EEG and MRI biomarkers in MOGAD patients with epilepsy, highlighting potential early indicators for refractory epilepsy and improved treatment outcomes.
Despite the availability of antiseizure medications approved for Dravet syndrome, a recent survey presented at AES 2025 showed that these therapies remain underutilized in patients.
Serum Albumin Levels Can Predict Increased Cancer Risk in Hemodialysis
1.
Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.
2.
Achieves a High Disease Control Rate in Head and Neck BCC with Vismodegib-RT Regimen.
3.
According to research, hospitals can save money and help cancer patients by implementing a basic intervention.
4.
In NPM1-mutated acute myeloid leukemia, MRD Correlates with Allo-Transplant Benefit.
5.
Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness
1.
Florinef: Understanding Its Uses and Side Effects
2.
Radioligand Therapy Advances: PSMA, Neuroendocrine, and Solid Tumor Clinical Insights
3.
Future of Oncology: Targeted Therapies & Collaborative Innovation Shaping Cancer Care in the USA
4.
Understanding Fibrosarcoma: What You Need to Know
5.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
2.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
3.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation